Submitted by web@researchtop... on Thu, 07/18/2013 - 16:40
iJournal Club - Lung Cancer: 2013
iJournal Club is a unique CME activity that attempts to distill the overwhelming number of important publications and conference presentations in lung cancer in 2012 and 2013 into a convenient summary of the most clinically relevant papers. Featuring commentary from Drs Ramaswamy Govindan, Rogerio C Lilenbaum and Thomas J Lynch Jr.
ASCO 2013 Abstracts
- Results from RTOG-0617 Phase III trial of standard- versus high-dose conformal chemoradiation therapy with or without cetuximab for Stage III NSCLC
- Activity and safety of the engineered MPDL3280A PD-L1 antibody in NSCLC and an evaluation of its activity by PD-L1 expression
- BRF113928: A Phase II study of dabrafenib in BRAF V600E mutation-positive NSCLC
- Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC
- Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged NSCLC
- Tumor profiling in advanced NSCLC with the assessment of biomarkers for EGFR, HER2, KRAS, BRAF, PI3KCA and EML4-ALK from 10,000 samples
- Results from 2 Phase III studies with maintenance pemetrexed and/or bevacizumab in patients with advanced nonsquamous NSCLC
- Predictive utility of VeriStrat® for determining survival outcome with erlotinib versus chemotherapy as second-line therapy for inoperable NSCLC
- Feasibility of a biology-driven trial based on baseline tumor ERCC1 protein levels and EGFR mutations in the adjuvant setting
EGFR Mutations; EGFR TKIs
- EGFR exon 20 insertion mutations in NSCLC
- EURTAC: Erlotinib versus standard first-line chemotherapy for EGFR-mutant advanced NSCLC
- LUX-Lung 3: Afatinib versus pemetrexed/cisplatin as first-line treatment for EGFR-mutant, advanced NSCLC
- Afatinib/cetuximab in EGFR-mutant advanced NSCLC resistant to EGFR inhibitors
- PARAMOUNT: Maintenance pemetrexed after cisplatin/pemetrexed for advanced nonsquamous NSCLC
- SELECT: Adjuvant erlotinib in EGFR-mutant NSCLC
- Response and toxicity of neoadjuvant erlotinib
- Irreversible pan-HER inhibitor dacomitinib versus erlotinib in advanced NSCLC